Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
KRAS inhibitor |
| gptkbp:alsoKnownAs |
gptkb:sotorasib
|
| gptkbp:approvalYear |
2021-05-28
|
| gptkbp:approvedBy |
adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
|
| gptkbp:ATCCode |
L01XX72
|
| gptkbp:CASNumber |
2296729-00-3
|
| gptkbp:chemicalFormula |
C30H30FN7O2
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Amgen
|
| gptkbp:firstBook |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
AMG 510
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Lumakras
|
| gptkbp:mechanismOfAction |
covalent inhibitor of KRAS G12C
|
| gptkbp:molecularWeight |
560.6 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL4297598
137323744 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hepatotoxicity |
| gptkbp:target |
KRAS G12C mutation
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:KRAS_(human)
gptkb:RMC-4630 gptkb:Sotorasib |
| gptkbp:bfsLayer |
7
|